Biotech | August 24, 2021
DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
CDSCO to fast-track trials and approval for COVID19 vaccine
Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.
It works as an adjunct to standard care based on robust clinical trials
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Subscribe To Our Newsletter & Stay Updated
